Svante Pääbo was awarded the Nobel Prize in Physiology or Medicine for his discoveries in human evolution; the amyotrophic lateral sclerosis (ALA drug AMX0035 was priced at $158,000 per year or about $12,500 per 28-day prescription; more than 16,000 Americans died of combination cancer and COVID-19 in the first 10 months of the pandemic.
The Nobel Prize in Physiology or Medicine was awarded today to Svante Pääbo for his discoveries in human evolution, The Associated Press reported. Pääbo is a Swedish scientist who spent decades trying to extract DNA from 40,000-year-old bones, which eventually resulted in the unveiling of the Neanderthal genome in 2010. According to the award’s panel, his findings provided key insights into the immune system of modern humans and allowed researchers to compare our genome with that of other hominins, the Neanderthals and Denisovans, and understand the connection between the species.
Amylyx Pharmaceuticals priced its newly FDA-approved treatment for amyotrophic lateral sclerosis (ALS) at $158,000 per year or about $12,500 per 28-day prescription in the United States, Reuters reported. AMX0035 (Relyvrio) was priced slightly lower than Mitsubishi Tanabe's edaravone (Radicava), which costs about $170,000 a year, but much higher than generic drug riluzole. Amylyx decided on the cost after meeting with patients, insurers, and other stakeholders while also thinking about funding future research, and plans to make the ALS drug available at no cost to US patients who are uninsured or underinsured under certain conditions. Data from a late-stage trial with about 600 patients will be expected in 2024.
Between March 1, 2020, and December 31, 2020, more than 16,000 Americans died of combination cancer and COVID-19, CIDRAP reported. In the first 10 months of the pandemic, according to a study published in JAMA Oncology, COVID-19 was an underlying cause of 3142 deaths from cancer, while cancer contributed to 13,419 deaths from COVID-19. Deaths caused by both occurred more often in large cities in November and December among individuals aged 85 and older, patients admitted to hospitals or living in long-term care facilities, and patients who were American Indian, Alaska Native, Black, or Hispanic.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More